TransMedics Group (NASDAQ:TMDX) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded TransMedics from “sell” to “hold.” Across analysts cited, the stock had five Buy and seven Hold ratings, with an average price target of $118.60.
• TransMedics reported quarterly revenue of $203.0 million, up 41.1% year over year, and EPS of $0.51, both above analyst estimates. The company also raised its 2026 revenue outlook to $764 million–$774 million.
• Some catalysts have been pushed to early 2027: ENHANCE Part B and DENOVO developments are delayed, while quarterly EPS was down from $0.66 a year earlier despite beating estimates.

TransMedics Group (NASDAQ:TMDX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages also recently issued reports on TMDX. Weiss Ratings raised TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. UBS Group decreased their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Zacks Research raised shares of TransMedics Group from a "strong sell" rating to a "hold" rating in a research report on Monday, November 2nd. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $95.00 to $120.00 and gave the stock a "buy" rating in a report on Friday. Finally, TD Cowen restated a "buy" rating and set a $120.00 target price on shares of TransMedics Group in a research note on Tuesday, September 8th. Five analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of "Hold" and an average target price of $118.60.

TransMedics Group Price Performance

Shares of TMDX stock opened at $88.24 on Friday. The firm has a market capitalization of $3.05 billion, a P/E ratio of 23.91, a P/E/G ratio of 0.92 and a beta of 2.14. The stock has a 50 day moving average price of $79.61 and a 200 day moving average price of $93.17. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.21. The business had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.66 EPS. As a group, sell-side analysts predict that TransMedics Group will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director David Weill bought 1,336 shares of the business's stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Braidwell LP increased its holdings in shares of TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company's stock valued at $40,497,000 after purchasing an additional 280,324 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in TransMedics Group by 5.5% during the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company's stock valued at $51,355,000 after purchasing an additional 26,969 shares during the period. Wellington Management Group LLP lifted its stake in TransMedics Group by 6.1% in the second quarter. Wellington Management Group LLP now owns 515,973 shares of the company's stock worth $34,271,000 after purchasing an additional 29,500 shares during the last quarter. Congress Asset Management Co. increased its position in shares of TransMedics Group by 11.0% in the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company's stock valued at $21,109,000 after acquiring an additional 25,118 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in TransMedics Group by 19.4% in the 1st quarter. Principal Financial Group Inc. now owns 231,433 shares of the company's stock valued at $23,007,000 after purchasing an additional 37,656 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company's primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.